EMPORIA2
Research type
Research Study
Full title
A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE DOSE LEVELS OF PF-07038124 OINTMENT FOR 12 WEEKS IN PARTICIPANTS 12 YEARS AND OLDER AND WITH MILD-TO-MODERATE ATOPIC DERMATITIS OR MILD-TO-SEVERE PLAQUE PSORIASIS
IRAS ID
1005770
Contact name
Sanela Tarabar
Contact email
Sponsor organisation
Pfizer Inc
Clinicaltrials.gov Identifier
Research summary
Summary of Research\nThis study will explore the effectiveness, safety and tolerance, and levels of the drug in the blood of an investigational ointment, PF-07038124, which is being developed to treat Atopic Dermatitis (AD) and Plaque Psoriasis (PsO).\nPF-07038124 is a potent and selective PDE4 (phosphodiesterase 4) inhibitor intended to be used for topical administration for the treatment of AD and PsO.\nThere will be about 240 people taking part in this study. There will be about 120 people with mild-to-moderate Atopic Dermatitis and about 120 people with mild-to-severe Plaque Psoriasis. The study is taking place at approximately 50 research sites in about 5 countries.\n\nSummary of Results\nPlease see the lay summary of the study results available on the below website.\nhttps://www.pfizer.com/science/clinical-trials/plain-language-study-results-summaries/c3941005
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
22/NW/0312
Date of REC Opinion
18 Nov 2022
REC opinion
Further Information Favourable Opinion